The Department of Defense has released pre-announcements for the Kidney Cancer Research Program managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP) to allow investigators time to plan and develop ideas for submission to the anticipated FY19 funding opportunities.
FY19 funding opportunities are anticipated for the following KCRP programs:
Concept Award
- Investigators at all academic levels.
- Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.
- Emphasis on innovation.
- Funding for clinical trials not allowed.
- Preliminary data not allowed.
- Blinded review.
- Maximum funding of $75,000 for direct costs (plus indirect costs) over a period of 1 year.
Idea Development Award
- Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or
- Early Career Investigators: Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.
- Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
- Preliminary data required.
- Innovation and Impact the most important review criteria.
- Funding for clinical trials not allowed.
- FY19 KCRP Areas of Emphasis strongly encouraged.
- Maximum funding of $400,000 in direct costs (plus indirect costs) over a period of 2 years.
Translational Research Partnership Award
- Investigators at or above the level of Assistant Professor (or equivalent).
- Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.
- Supports translational correlative studies.
- Preliminary data required.
- Funding for clinical trials not allowed.
- Maximum funding of $600,000 for direct costs (plus indirect costs) over a period of 3 years.
Kidney Cancer Academy Dean Award
- Dean must be an independent, established kidney cancer researcher with a record of kidney cancer research funding and publications in peer-reviewed journals.
- Supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership.
- Academy Dean will oversee an interactive virtual academy of ECIs and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the ECIs.
- Maximum funding of $500,000 for direct costs (plus indirect costs) over a period of 4 years.
Kidney Cancer Academy Early Career Investigator Award
- Within 3 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline.
- Letter attesting to eligibility required.
- Supports addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
- ECIs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
- Requires Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding.
- Designated Mentor not required to be at the same institution as the ECI.
- Preliminary data required.
- Clinical trials allowed.
- Maximum funding of $725,000 for direct costs (plus indirect costs) over a period of 4 years.
Clinical Consortia Award
- Independent Investigators at or above the level of Assistant Professor (or equivalent).
- Supports development of a consortium that will facilitate rapid execution of collaborative Phase II or Phase I/II clinical trials to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease impact of kidney cancer.
- Funds may not be used for research or development of clinical protocols.
- Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.
- One (1) Coordinating Center and three (3) Clinical Trial Sites will be selected and be jointly responsible for proposing, selecting, and conducting trials.
- Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer.
- Consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends.
- Coordinating Center: Maximum funding of $3,000,000 for direct costs (plus indirect costs) over a period of 3 years.
- Clinical Trial Sites: Maximum funding of $600,000 for direct costs (plus indirect costs) over a period of 3 years.
Descriptions of each of the anticipated funding opportunities, eligibility, key mechanism elements, and funding can be found in the Program pre-announcement. FY19 pre-announcements can be found in the CDMRP home page features at https://cdmrp.army.mil.
Subsequent notifications will be sent when the program announcements/funding opportunities are released.
Filed Under: Funding Opportunities